Madrigal Pharma (MDGL) Tops Q1 EPS by 94c

Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.25), $0.94 better than the analyst estimate of ($4.19). Revenue for the quarter came in at $311.34 million versus the consensus estimate of $301.29 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Evolv Technology adds 70 customers in Q2, expands bag screening
• CXApp announces 1-for-50 reverse stock split effective Aug. 18